title: Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients.
abstract: Cytomegalovirus is the most common viral pathogen that affects solid organ transplant recipients. It directly causes fever, myelosuppression, and tissue-invasive disease, and indirectly, it negatively impacts allograft and patient survival. Nucleic acid amplification testing is the preferred method to confirm the diagnosis of CMV infection. Prevention of CMV disease using antiviral prophylaxis or preemptive therapy is critical in the management of transplant patients. Intravenous ganciclovir and oral valganciclovir are the first line drugs for antiviral treatment. This article provides a comprehensive review of the current epidemiology, diagnosis, prevention and treatment of CMV infection in solid organ transplant recipients.
authors.affiliation: Division of Infectious Diseases, The William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN 55905, USA. razonable.raymund@mayo.edu
authors.forename: Raymund R
authors.initials: RR
authors.lastname: Razonable
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D018890:Chemoprevention / Q000379:methods; D003587:Cytomegalovirus / Q000145:classification / Q000302:isolation & purification; D003586:Cytomegalovirus Infections / Q000175:diagnosis* / Q000188:drug therapy* / Q000517:prevention & control; D015774:Ganciclovir / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D025202:Molecular Diagnostic Techniques; D009894:Opportunistic Infections / Q000188:drug therapy* / Q000453:epidemiology* / Q000517:prevention & control; D016133:Polymerase Chain Reaction; D014180:Transplantation; D019737:Transplants; D016896:Treatment Outcome; D000077562:Valganciclovir; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir